Japan’s health ministry approved a slew of new medicines on September 25 including multiple “first of its kind” products, among them being GlaxoSmithKline’s respiratory syncytial virus (RSV) vaccine Arexvy as well as Eisai’s Alzheimer’s therapy Leqembi (lecanemab).Arexvy became the first…
HOME > ORGANIZATION
ORGANIZATION
- Priority of Japan Investment Lowered at 27% of Multinational Firms: JPMA Poll
November 2, 2022
- JPMA Applauds Drug Discovery Startup Support in New Economic Package
October 31, 2022
- Japan Needs New Forum for Top-Level Dialogue Including Global CEOs: PhRMA Chair
October 28, 2022
- Over 80% of Wholesaler Reps Say Shipment Adjustments Take Up Most of Their Time: Survey
October 21, 2022
- Look at Drug Prices as Long-Term Investment, Not as Cost: EFPIA President
October 7, 2022
- EFPIA Chief Prods Japan on Mutual Trial Data Recognition, Cooperation to Boost Attractiveness to Rival US, China
October 7, 2022
- EFPIA Japan Appoints Takafumi Horii as New Vice Chair
October 6, 2022
- JMA Chuikyo Rep Urges Savings from Off-Year Drug Price Cuts to Be Allocated to Medical Fees
October 5, 2022
- Generic Use Rate at 79.8% in April-June, Flat YOY: JGA
September 29, 2022
- Policy Veterans’ Group Proposes Simple Drug Price Maintenance Scheme for Patented Meds
September 28, 2022
- 3 Cell & Gene Therapies Make Up More than Half of Top 100 Bills in FY2021: Payer
September 22, 2022
- Sales Reps in Japan Decrease for 8 Years Straight as Voluntary Redundancy Weighs: FY2021 Report
September 21, 2022
- Shionogi’s COVID Pill Might Not Be Applicable for Emergency Approval: JPMA Exec
September 16, 2022
- JPMA Managing Director Tanaka to Retire, Ex-Chugai Official to Take Over
September 16, 2022
- JPMA to Present Proposal on Value-Based Drug Pricing at Upcoming Panel Hearing
September 16, 2022
- FPMAJ Investigating Supply Status for 60% of All Drugs, Tally Due Out by Year-End
September 14, 2022
- FPMAJ-Eyed Overhaul of Price Revision Rules Likely to Curb Price Falls, Cover JP-Listed Meds, Essential Drugs and More
September 9, 2022
- Rapid Removal of NHI-Market Price Gap Will Cause Chaos: Pharmacy Industry Chief
September 9, 2022
- JMA President Confirms Need for Profits from NHI-Market Price Gap
September 8, 2022
- Ex-MHLW Official Isobe, Now at Self-Medication Group, Touts OTC Use to Soften Impact of Off-Year Re-Pricing
September 7, 2022
ページ
In the run-up to FY2024 budget requests this summer, there were growing hopes in the pharmaceutical industry that the government's de-facto cap on increases in social security spending would finally be lifted. That did not happen, despite strong calls from…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…